Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2018

01-04-2018 | Original Article

Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats

Authors: Mostafa Shahrezaee, Ahmad Oryan, Farshid Bastami, Sepanta Hosseinpour, Mohammad Hossein Shahrezaee, Amir Kamali

Published in: Endocrine | Issue 1/2018

Login to get access

Abstract

Purpose

In addition to lipid-lowering properties, statins have been suggested to affect bone turnover by increasing the osteoblastic bone formation and blocking the osteoclastogenesis. However, there are many controversial reports regarding the beneficial effect of statins on osteoporosis. In this study, we investigated the therapeutic effects of the most important lipophilic statins administered orally for 60 days to the ovariectomized (OVX) female Sprague–Dawley rats and compared the effects on different harvested trabecular and compact bones.

Methods

Thirty female rats were divided into five equal groups including the normal rats, untreated OVX rats (negative control), and the OVX rats treated with atorvastatin (20 mg/kg/day), simvastatin (25 mg/kg/day), and lovastatin (20 mg/kg/day). The osteoporotic animals were treated daily for 60 days and euthanized at the end of experiments. The effectiveness of these treatments was evaluated by biomechanical testing, histopathologic, histomorphometric, micro-CT scan, real-time PCR, and serum biochemical analysis. Moreover, the hepatotoxicity and rhabdomyolysis related with these treatments were assessed by biochemistry analysis and histopathological evaluation.

Results

The results and statistical analysis showed that systemic delivery of simvastatin and lovastatin significantly increased serum calcium level, expression of osteogenic genes, bone mineral density (BMD), and biomechanical properties in comparison to the untreated OVX rats, especially in trabecular bones (P < 0.05). The results of different analysis also indicated that there was no statistical difference between the atorvastatin-treated animals and the negative control. Among all treatments, only atorvastatin showed an evident hepatotoxicity and myopathy.

Conclusions

It was concluded that the lovastatin and simvastatin efficiently ameliorated the OVX-induced osteoporosis. Moreover, the simvastatin-treated animals showed more resemblance to the normal group in terms of BMD, expression of osteogenic genes, serum biochemical parameters, histomorphometric findings, and biomechanical performance with no significant side-effects.
Literature
1.
2.
Z.A. Cole, E.M. Dennison, C. Cooper, Osteoporosis epidemiology update. Curr. Rheumatol. Rep. 10(2), 92–96 (2008)CrossRefPubMed
3.
S.B. Jadhav, G.K. Jain, Statins and osteoporosis: new role for old drugs. J. Pharm. Pharmacol. 58(1), 3–18 (2006)CrossRefPubMed
4.
5.
G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012)CrossRefPubMed
6.
7.
8.
A. Oryan, A. Kamali, A. Moshiri, Potential mechanisms and applications of statins on osteogenesis: current modalities, conflicts and future directions. J. Control. Release 215, 12–24 (2015)CrossRefPubMed
9.
A. Moshiri, M. Shahrezaee, B. Shekarchi, A. Oryan, K. Azma, Three-dimensional porous gelapin–simvastatin scaffolds promoted bone defect healing in rabbits. Calcif. Tissue Int. 96(6), 552–564 (2015)CrossRefPubMed
10.
A. Moshiri, A.M. Sharifi, A. Oryan, Role of simvastatin on fracture healing and osteoporosis: a systematic review on in vivo investigations. Clin. Exp. Pharmacol. Physiol. 43(7), 659–684 (2016)CrossRefPubMed
11.
A. Oryan, S. Alidadi, A. Moshiri, N. Maffulli, Bone regenerative medicine: classic options, novel strategies, and future directions. J. Orthop. Surg. Res. 9(1), 18 (2014)CrossRefPubMedPubMedCentral
12.
A.N. Tsartsalis, C. Dokos, G.D. Kaiafa, D.N. Tsartsalis, A. Kattamis, A.I. Hatzitolios, C.G. Savopoulos, Statins, bone formation and osteoporosis: hope or hype. Hormone 11(2), 126–139 (2012)CrossRef
13.
J.O. Jansen, J.M. Lord, D.R. Thickett, M.J. Midwinter, D.F. McAuley, F. Gao, Clinical review: statins and trauma–a systematic review. Crit. Care 17(3), 227 (2013)CrossRefPubMedPubMedCentral
14.
Z. Du, J. Chen, F. Yan, N. Doan, S. Ivanovski, Y. Xiao, Serum bone formation marker correlation with improved osseointegration in osteoporotic rats treated with simvastatin. Clin. Oral. Implant. Res. 24(4), 422–427 (2013)CrossRef
15.
I. Gradosova, H. Zivna, K. Svejkovska, V. Palicka, A. Tichy, P. Zivny, The role of atorvastatin in bone metabolism in male albino Wistar rats. Die Pharm. Int. J. Pharm. Sci. 66(8), 606–610 (2011)
16.
C. Liu, Z. Wu, H. Sun, The effect of simvastatin on mrna expression of transforming growth factor-β1, bone morphogenetic protein-2 and vascular endothelial growth factor in tooth extraction socket. Int. J. Oral. Sci. 1(2), 90–98 (2009)CrossRefPubMedPubMedCentral
17.
W. Wang, J.S. Nyman, H.E. Moss, G. Gutierrez, G.R. Mundy, X. Yang, F. Elefteriou, Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J. Bone Mineral. Res. 25(7), 1658–1667 (2010)CrossRef
18.
J.P. Issa, C. Ingraci de Lucia, B.G. Dos Santos Kotake, M. Goncalves Gonzaga, F.A. Tocchini de Figueiredo, D. Mizusaki Iyomasa, A.P. Macedo, E. Ervolino, The effect of simvastatin treatment on bone repair of femoral fracture in animal model. Growth Factors 33(2), 139–148 (2015)CrossRefPubMed
19.
Y. Ayukawa, A. Okamura, K. Koyano, Simvastatin promotes osteogenesis around titanium implants. Clin. Oral. Implant. Res. 15(3), 346–350 (2004)CrossRef
20.
N.I. Ibrahim, M.F. Khamis, M.F.M. Yunoh, S. Abdullah, N. Mohamed, A.N. Shuid, Targeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: micro-computed tomography and biomechanical evaluation. PloS. One 9(12), e115595 (2014)CrossRef
21.
S. Chuengsamarn, S. Rattanamongkoulgul, S. Suwanwalaikorn, S. Wattanasirichaigoon, L. Kaufman, Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46(4), 1011–1015 (2010)CrossRefPubMed
22.
T. Majima, Y. Komatsu, A. Fukao, K. Ninomiya, T. Matsumura, K. Nakao, Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr. J. 54(1), 145–151 (2007)CrossRefPubMed
23.
B. Chang, J. Yang, H. Li, S. Lu, L. Chen, P. Fang, Effects of atorvastatin on bone metabolism and bone mineral density in Wistar rats. Die Pharm. 66(7), 535–537 (2011)
24.
K. Esposito, A. Capuano, L. Sportiello, A. Giustina, D. Giugliano, Should we abandon statins in the prevention of bone fractures? Endocrine 44(2), 326–333 (2013)CrossRefPubMed
25.
F.J. Maritz, M.M. Conradie, P.A. Hulley, R. Gopal, S. Hough, Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler. Thromb. Vasc. Biol. 21(10), 1636–1641 (2001)CrossRefPubMed
26.
S.B. Jadhav, P.S. Narayana Murthy, M.M. Singh, G.K. Jain, Distribution of lovastatin to bone and its effect on bone turnover in rats. J. Pharm. Pharmacol. 58(11), 1451–1458 (2006)CrossRefPubMed
27.
R. Ogasawara, Y. Furuya, H. Sasaki, M. Yoshinari, Y. Yajima, Effects of oral administration of simvastatin on bone formation in senile osteoporosis rat. J. Hard Tissue Biol. 22(4), 461–472 (2013)CrossRef
28.
M. Thapar, M.W. Russo, H.L. Bonkovsky, Statins and Liver Injury. Gastroenterol. Hepatol. 9(9), 605–606 (2013)
29.
J. Sidaway, Y. Wang, A.M. Marsden, T.C. Orton, F.R. Westwood, C.T. Azuma, R.C. Scott, Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica 39(1), 90–98 (2009)CrossRefPubMed
30.
V. Alt, U. Thormann, S. Ray, D. Zahner, L. Dürselen, K. Lips, T. El Khassawna, C. Heiss, A. Riedrich, G. Schlewitz, A. Ignatius, M. Kampschulte, H. von Dewitz, S. Heinemann, R. Schnettler, A. Langheinrich, A new metaphyseal bone defect model in osteoporotic rats to study biomaterials for the enhancement of bone healing in osteoporotic fractures. Acta Biomater. 9(6), 7035–7042 (2013)CrossRefPubMed
31.
32.
N. El-Nabarawi, M. El-Wakd, M. Salem, Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug. Des. Dev. Ther. 11, 1383–1391 (2017)CrossRef
33.
A. Oryan, A. Bigham-Sadegh, F. Abbasi-Teshnizi, Effects of osteogenic medium on healing of the experimental critical bone defect in a rabbit model. Bone 63, 53–60 (2014)CrossRefPubMed
34.
M. Yamauchi, T. Yamaguchi, K. Nawata, K.-i Tanaka, S. Takaoka, T. Sugimoto, Increased low-density lipoprotein cholesterol level is associated with non-vertebral fractures in postmenopausal women. Endocrine 48(1), 279–286 (2015)CrossRefPubMed
35.
36.
Y.P. Kharode, M.C. Sharp, P.V. Bodine, Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Osteoporosisc 455, 111–124 (2008)CrossRef
37.
M.M. Elkomy, F.G. Elsaid, Anti-osteoporotic effect of medical herbs and calcium supplementation on ovariectomized rats. J. Basic Appl. Zool. 72(Supplement C), 81–88 (2015)CrossRef
38.
P.P. Lelovas, T.T. Xanthos, S.E. Thoma, G.P. Lyritis, I.A. Dontas, The laboratory rat as an animal model for osteoporosis research. Comp. Med. 58(5), 424–430 (2008)PubMedPubMedCentral
39.
S.R. Shah, C.A. Werlang, F.K. Kasper, A.G. Mikos, Novel applications of statins for bone regeneration. Natl. Sci. Rev. 2(1), 85–99 (2015)CrossRefPubMed
40.
J.B. Park, The use of simvastatin in bone regeneration. Med. Oral. Patol. Oral. Cir. Bucal 14(9), e485–e488 (2009)PubMed
41.
T. Kawane, S. Terashima, I. Kurahashi, T. Yanagawa, H. Yoshida, N. Horiuchi, Atorvastatin enhances bone density in ovariectomized rats given 17β-estradiol or human parathyroid hormone (1–34). Endocrine 24(2), 121–129 (2004)CrossRefPubMed
42.
H.G. Bone, D.P. Kiel, R.S. Lindsay, E.M. Lewiecki, M.A. Bolognese, E.T. Leary, W. Lowe, M.R. McClung, Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J. Clin. Endocrinol. Metab. 92(12), 4671–4677 (2007)CrossRefPubMed
43.
Y. Uyar, Y. Baytur, U. Inceboz, B.C. Demir, G. Gumuser, K. Ozbilgin, Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas 63(3), 261–267 (2009)CrossRefPubMed
44.
S. Lin, J. Huang, Z. Fu, Y. Liang, H. Wu, L. Xu, Y. Sun, W.Y. Lee, T. Wu, L. Qin, The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats. Calcif. Tissue Int. 96(6), 541–551 (2015)CrossRefPubMed
45.
I. Gradosova, H. Zivna, V. Palicka, S. Hubena, K. Svejkovska, P. Zivny, Protective effect of atorvastatin on bone tissue in orchidectomised male albino Wistar rats. Eur. J. Pharmacol. 679(1-3), 144–150 (2012)CrossRefPubMed
46.
47.
T. An, J. Hao, S. Sun, R. Li, M. Yang, G. Cheng, M. Zou, Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos. Int. 28(1), 47–57 (2017)CrossRefPubMed
48.
L.J. Qiao, K.L. Kang, J.S. Heo, Simvastatin promotes osteogenic differentiation of mouse embryonic stem cells via canonical Wnt/β-catenin signaling. Mol. Cells 32(5), 437–444 (2011)CrossRefPubMedPubMedCentral
49.
J. Pagkalos, J.M. Cha, Y. Kang, M. Heliotis, E. Tsiridis, A. Mantalaris, Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J. Bone Mineral. Res. 25(11), 2470–2478 (2010)CrossRef
50.
J. Jose, F.A.A. Al-Tamimi, M.M. Helal, B. Jimmy, Q. Al Riyami, Statin associated associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman. Oman Med. J. 29(5), 351–357 (2014)CrossRefPubMedPubMedCentral
51.
A.T. Clarke, P.C. Johnson, G.C. Hall, I. Ford, P.R. Mills, High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS. One 11(3), e0151587 (2016)CrossRefPubMedPubMedCentral
52.
S.O. El-Ganainy, A. El-Mallah, D. Abdallah, M.M. Khattab, M.M. Mohy El-Din, A.S. El-Khatib, Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model. Toxicology 359–360(Supplement C), 29–38 (2016)CrossRefPubMed
53.
K. Mukaiyama, M. Kamimura, S. Uchiyama, S. Ikegami, Y. Nakamura, H. Kato, Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin. Exp. Res. 27(4), 413–418 (2015)CrossRefPubMed
54.
H.A. Fink, S. Litwack-Harrison, B.C. Taylor, D.C. Bauer, E.S. Orwoll, C.G. Lee, E. Barrett-Connor, J.T. Schousboe, D.M. Kado, P.S. Garimella, K.E. Ensrud, Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the Osteoporotic Fractures in Men (MrOS) Study. Osteoporos. Int. 27(1), 331–338 (2016)CrossRefPubMed
55.
A. Panico, G.A. Lupoli, F. Marciello, R. Lupoli, M. Cacciapuoti, A. Martinelli, L. Granieri, D. Iacono, G. Lupoli, Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med. Sci. Monit. 17(8), Cr442–Cr448 (2011)CrossRefPubMedPubMedCentral
56.
A. Egan, E. Colman, Weighing the benefits of high-dose simvastatin against the risk of myopathy. New Engl. J. Med. 365(4), 285–287 (2011)CrossRefPubMed
Metadata
Title
Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats
Authors
Mostafa Shahrezaee
Ahmad Oryan
Farshid Bastami
Sepanta Hosseinpour
Mohammad Hossein Shahrezaee
Amir Kamali
Publication date
01-04-2018
Publisher
Springer US
Published in
Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1531-6

Other articles of this Issue 1/2018

Endocrine 1/2018 Go to the issue

Original Article

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

Original Article

Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress

Original Article

Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation

Original Article

Body composition and sarcopenia in patients with chronic obstructive pulmonary disease

Original Article

MiR-145 improves macrophage-mediated inflammation through targeting Arf6

Endocrine Surgery

Hybrid techniques and patients’ safety in implementing transoral sublingual thyroidectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits